4th Quarter - Amendment

STANTON PARK GROUP for VERTEX PHARMACEUTICALS INCORPORATED

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Access to rare and orphan disease therapeutics under the enactment of the ACA; FDA regulatory pathways for pharmaceuticals; HR 460 the Patients Access to Treatment Act of 2013; Awareness of Cystic Fibrosis

LobbyistCovered position, as disclosed
JAMES DERDERIAN —
VALERIE HENRY —
RICHARD MATHER RUSSELL —
EMILY SHETTY —
ERIN STRAWN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 460 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.